BIO241220C180000
- 159.18
- 0.000.00%
Bio-Rad Laboratories Newsroom
Protein Sequencing Market Analysis and Forecast 2024-2033, Featuring Profiles of Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific, Shimadzu, Selvita, Bruker, Merck, Seer and More
Bio-Rad Laboratories Down Over 6%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk
What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity?
Calculating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
Express News | CORRECTION: Bioage Labs Ticker Is "BIOA"
Express News | BioAge Labs To Present New Preclinical Data For Lead Product Candidate Azelapragor At ObesityWeek 2024
Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Express News | Bio-Rad Laboratories Shares Are Trading Higher After Citigroup Maintained a Buy Rating on the Stock and Raised Its Price Target From $400 to $450
Bio-Rad Laboratories Shares Are Trading Higher After Citigroup Maintained a Buy Rating on the Stock and Raised Its Price Target From $400 to $450.
Express News | NYSE Halt Bio-Rad Labs B Add Info Lst $334.850000
A Quick Look at Today's Ratings for Bio-Rad Laboratories(BIO.US), With a Forecast Between $360 to $469
Bio-Rad Laboratories Third Quarter 2024 Earnings: EPS: US$23.37 (Vs US$3.65 in 3Q 2023)
Bio-Rad Labs Misses Q3 Estimates for Profit, Revenue
Bio-Rad Laboratories | 10-Q: Q3 2024 Earnings Report
Bio-Rad Laboratories Is Maintained at Outperform by RBC Capital
Bio-Rad Laboratories Analyst Ratings
Bio-Rad Laboratories Up Over 5%, On Track for Largest Percent Increase Since December 2023 -- Data Talk
Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference
RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $469
Citi Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $450